Additional COVID-19 vaccines recognised for inbound travellers

The Australian Government now recognises 10 COVID-19 vaccines for the purposes of inbound travel to Australia. Recent approvals include Sputnik V (Gamaleya Research Institute) and Nuvaxovid (by Biocelect Pty Ltd on behalf of Novavax Inc) to be used in Australia.

24 Jan 2022

The Australian Government now recognises 10 COVID-19 vaccines for the purposes of inbound travel to Australia.

Recent approvals include Sputnik V (Gamaleya Research Institute) and Nuvaxovid (by Biocelect Pty Ltd on behalf of Novavax Inc) to be used in Australia.

The first protein vaccine to be recognised by Australia, Nuvaxovid is designed to be given in two (2) doses, three (3) weeks apart.

As studies into the use of Nuvaxovid as a booster and for use in paediatric patients are continuing, it has only received approval so far as a primary vaccination.

The provisional approval is subject to strict conditions that must be met by the manufacturer, including data on the long-term efficacy and safety of the vaccine.

The Australian Government reached an agreement with Novavax in January 2021 to purchase 51 million doses. The first shipment is expected to arrive in Australia within the next month.

International students in Australia have free access to the COVID-19 vaccine and boosters. For more information on the recognition of these vaccines, visit Approved and recognised vaccines page in the Study Australia Latest travel and visa advice section.